Search Result

Results for "

HL60/s

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (5) Apoptosis (5) Bacterial (2) Bcl-2 Family (2) Bombesin Receptor (2) Cannabinoid Receptor (1) Caspase (2) CDK (2) Checkpoint Kinase (Chk) (2) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Drug Derivative (1) Endogenous Metabolite (1) Farnesyl Transferase (1) FLT3 (1) HDAC (2) Histone Methyltransferase (1) Isotope-Labeled Compounds (1) Molecular Glues (1) mTOR (1) Parasite (1) Phosphatase (1) PI3K (1) Polo-like Kinase (PLK) (1) PROTACs (2) RANKL/RANK (1) Reference Standards (1) Src (1) VEGFR (1) Wee1 (1)
By Research Areas:	Cancer (30) Infection (4) Inflammation/Immunology (2) Metabolic Disease (1)

By Targets:

ADC Payload (5)

Apoptosis (5)

Bacterial (2)

Bcl-2 Family (2)

Bombesin Receptor (2)

Cannabinoid Receptor (1)

Caspase (2)

CDK (2)

Checkpoint Kinase (Chk) (2)

Cytochrome P450 (1)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (1)

Drug Derivative (1)

Endogenous Metabolite (1)

Farnesyl Transferase (1)

FLT3 (1)

HDAC (2)

Histone Methyltransferase (1)

Isotope-Labeled Compounds (1)

Molecular Glues (1)

mTOR (1)

Parasite (1)

Phosphatase (1)

PI3K (1)

Polo-like Kinase (PLK) (1)

PROTACs (2)

RANKL/RANK (1)

Reference Standards (1)

Src (1)

VEGFR (1)

Wee1 (1)

By Research Areas:

Cancer (30)

Infection (4)

Inflammation/Immunology (2)

Metabolic Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-103286

PD176252 2 Publications Verification	Bombesin Receptor	Cancer
PD176252 is a potent antagonist of neuromedin-B preferring (BB₁) and gastrin-releasing peptide-preferring (BB₂) receptor with K_is of 0.17 nM and 1 nM for human BB₁ and BB₂ receptors, and 0.66 nM, 16 nM for Rat BB₁ and BB₂ receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with *EC₅₀s of 0.31 and 0.66 μM in HL-60* cells.

HY-N1746

(2S)-2'-Methoxykurarinone 2'-O-Methylkurarinone	RANKL/RANK	Metabolic Disease Inflammation/Immunology Cancer
(2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .

HY-155066

FD274	PI3K mTOR Apoptosis	Cancer
FD274 is a highly potent PI3K/mTOR dual inhibitor with *IC₅₀s of 0.65 nM, 1.57 nM, 0.65 nM, 0.42 nM, and 2.03 nM against PI3Kα/β/γ/δ and mTOR, respectively. FD274 exhibits significant anti-proliferation of AML cell lines (HL-60* and MOLM-16). FD274 arrests HL-60 cell cycle at G1 phase and increases apoptosis. FD274 demonstrates dose-dependent inhibition of tumor growth in the HL-60 xenograft model. FD274 has the potential for acute myeloid leukemia research .

HY-N7634

Tectol	Farnesyl Transferase Parasite	Infection Cancer
Tectol, isolated from Lippia sidoides, exhibits significant activity against human leukemia cell lines HL60 and CEM . Tectol is a farnesyltransferase (FTase) inhibitor with *IC₅₀s of 2.09 and 1.73 μM for human and T. brucei* FTase, respectively. Tectol inhibits drug-resistant strain of P. falciparum (FcB1) with an IC₅₀ of 3.44 μM .

HY-N11928

Changnanic acid	Others	Cancer
Changnanic acid (schisandrin) is a triterpene compound with potential anti-tumor effects. Changnanic acid exhibits moderate cytotoxic activity against human tumor cell lines Bel-7402, MCF-7 and HL-60, with *IC₅₀*s of 100 μM, 100 μM and 50.51 μM respectively .

HY-112898

DC1SMe	ADC Payload	Cancer
DC1Sme, a DC1 derivative, exhibits IC₅₀ values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.

HY-175261

DHI1	CDK Wee1 Checkpoint Kinase (Chk)	Cancer
DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC₅₀ = 21.83 μM) and HL-60 (IC₅₀ = 19.14 μM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies .

HY-135122

DC10SMe	ADC Payload DNA Alkylator/Crosslinker	Cancer
DC10SMe is a DNA alkylator, can be used in the synthesis of antibody-drug conjugate (ADC). DC10SMe exhibits IC₅₀s of 15 pM, 12 pM, and 12 pM for Ramos, Namalwa, and HL60/s cancer cells, respectively .

HY-112900

DC41SMe	ADC Payload	Cancer
DC41SMe, a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with *IC₅₀*s ranging from 18-25 pM. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer .

HY-115754

S-(N-PhenethylthiocarbaMoyl)-L-cysteine PEITC-Cys	DNA/RNA Synthesis Cytochrome P450	Cancer
S-(N-PhenethylthiocarbaMoyl)-L-cysteine (PEITC-Cys), an anticarcinogenic agent, has antileukemic activity. S-(N-PhenethylthiocarbaMoyl)-L-cysteine inhibits DNA synthesis in HL60 cells . S-(N-PhenethylthiocarbaMoyl)-L-cysteine is a P450 inhibitor .

HY-159609

GSPT1 degrader-9	Molecular Glues	Cancer
GSPT1 degrader-9 (Compound F) is a cereblon-based molecular glue degrader for G1 to S phase transition protein 1 (GSPT1) that degrades GSPT1 with a rate of 95% (1 μM) GSPT1 and 86% (0.1 μM). GSPT1 degrader-9 inhibits the cell viability of HL-60 with an IC₅₀ of 9.2 nM .

HY-124122

BPTQ	VEGFR Checkpoint Kinase (Chk) Apoptosis Caspase Bcl-2 Family	Cancer
BPTQ is a potent inhibitor against VEGFR1 and CHK2 with IC₅₀ values of 0.54 and 1.70 µmol/L, respectively. BPTQ is also an intercalator of DNA with anticancer activities. BPTQ inhibits the proliferation of HL-60 cells by arresting cells at S and G2/M phase with an IC₅₀ value of 12 µmol/L. BPTQ also activates the mitochondria-mediated Apoptosis pathway by a decrease in mitochondrial membrane potential, increase in the Bax:Bcl-2 ratio and activation of caspases .

HY-124007

4-Iodo-SAHA ISAHA	HDAC	Cancer
4-Iodo-SAHA (1k) is an orally active class I and class II histone deacetylase (HDAC) inhibitor with *EC₅₀s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM for Skbr3, HT29, U937, JA16 and HL60* cell lines, respectively. 4-Iodo-SAHA (1k) can be used for the research of cancer .

HY-161687

Cisplatin/Dasatinib prodrug-1	Src	Cancer
Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with *IC₅₀*s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .

HY-161708

PROTAC FLT3/CDKs degrader-1	PROTACs CDK FLT3	Cancer
PROTAC FLT3/CDKs degrader-1 (Compound C3) is a degrader for cyclin-dependent kinases (DC₅₀ is 18.73 nM for CDK2) and the FMS-like tyrosine kinase 3 (FLT3). PROTAC FLT3/CDKs degrader-1 induces differentation of HL-60 (72.77% differentation at 6.25 nM), inhibits proliferation of AML cells, with *IC₅₀*s of 2.9-37 nM. PROTAC FLT3/CDKs degrader-1 is potential for ameliorating acute myeloid leukemia. (Pink: ligand for target protein FLT3/CDKs ligand-1 (HY-161709); Black: linker (HY-W012935); Black: ligand for E3 ligase Thalidomide 5-fluoride (HY-W087383))

HY-N10392

(S)-Erypoegin K	Apoptosis	Cancer
(S)-Erypoegin K is a potent anticancer agent. (S)-Erypoegin K shows potent anti-proliferative activity against HL-60 cells. (S)-Erypoegin K induces apoptosis .

HY-N10364

6β,7β-Epoxyasteriscunolide A	Others	Cancer
6β,7β-Epoxyasteriscunolide A, a sesquiterpenoid, shows cytotoxicity against the HL-60 and MOLT-3 leukemia cell lines, with *IC₅₀*s range 4.1-5.4 μM .

HY-N12108

Forphenicine	Phosphatase	Infection Inflammation/Immunology Cancer
Forphenicine is a bacterial metabolite that is found in S. fulvoviridis and an inhibitor of alkaline phosphatase. Forphenicine inhibits the growth of HL-60 leukemia cells at 10 µM. Forphenicine also increases survival in a guinea pig model of experimental autoimmune encephalomyelitis (EAE) .

HY-N15112

Pintulin	Others	Cancer
Pintulin can inhibit P388, L 1210, HL-60, KB and other tumor cell lines with *IC₅₀*s (μg/mL) of 0.8, 0.8, 0.8, 0.25, respectively. Pintulin has only very weak antibacterial activity against the microorganisms tested .

HY-N11651

Peganumine A	Others	Others
Peganumine A is a natural product that can be found in Peganum harmala. Peganumine A shows cytotoxicity with IC₅₀s of5.8, 38.5, 40.2, 55.4 µM for HL-60, MCF-7, PC-3, and HepG2 cells ,respectively .

HY-N10082

Trigoxyphin A	Others	Cancer
Trigoxyphin A is a oxygenated daphnane-type diterpenoids. Trigoxyphin A exhibites strong cytotoxic activity against HL60 and A549 with *IC₅₀*s of 0.27 and 7.5 μM, respectively .

HY-135124

DC44SMe	ADC Payload	Cancer
DC44SMe, a phosphate proagent of cytotoxic DNA alkylator DC44, can be used in the synthesis of antibody-drug conjugate (ADC). DC44SMe exhibits IC₅₀s of 2.0 nM, 2.8 nM, and 1.9 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC44SMe can be used for the targeted treatment of cancer .

HY-135123

DC4SMe	ADC Payload	Cancer
DC4SMe, a phosphate proagent of cytotoxic DNA alkylator DC4, can be used in the synthesis of antibody-drug conjugate (ADC). DC4SMe exhibits IC₅₀s of 1.9 nM, 2.9 nM, and 1.8 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC4SMe can be used for the targeted treatment of cancer .

HY-113455S1

9(S)-HODE-13C18 Alpha-dimorphecolic acid-¹³C₁₈	Isotope-Labeled Compounds Endogenous Metabolite Apoptosis Drug Derivative	Cancer
9(S)-HODE- ¹³C₁₈ ((+)-α-Dimophecolic acid- ¹³C₁₈) is ¹³C labeled 9S-HODE. 9S-HODE (Alpha-dimorphecolic acid) is an octadecadienoic acid and the main active derivative of linoleic acid, which can reduce the viability of HL-60 cells and induce apoptosis. 9S-HODE is rich in lipid peroxidation (LPO) products and is almost an ideal marker for LPO .

HY-168082

Dot1L-IN-8	Histone Methyltransferase	Cancer
Dot1L-IN-8 (Compound 15) is a potent Dot1L inhibitor. Dot1L-IN-8 inhibits HL-60, K562, MV4-11, HH, and KG-1 cells vitality with *IC₅₀*s of 0.45, 1.03, 0.68, 1.66, and 1.12 μM, respectively .

HY-N14415

Cochleamycin A	Bacterial	Infection Cancer
Cochleamycin A showed strong inhibitory activity against tumor cells, with *IC₅₀s (μg/mL) of P388, HL60*, K562, COL0205 and HT29 cells of 1.6, 14.0, 6.2, 16.5 and 19.1, respectively. Cochleamycin A also has anti-Gram-positive bacteria activity .

HY-168338

CB2 receptor agonist 8	Cannabinoid Receptor Caspase	Cancer
CB2 receptor agonist 8 (Compound 17) is an agonist for cannabinoid receptor 2 (CB2 receptor). CB2 receptor agonist 8 exhibits cytotoxicity in cells U87, RPMI 8226, HL-60, and L929 with *IC₅₀s of 91.03, 16.29, 23.51 and 564.6 μM, respectively. CB2 receptor agonist 8 activates caspase 3/7, increases the expressions of pro-apoptotic genes BAX, BAD, BIM and tumor suppressor genes p53, and induces apoptosis* in U87. CB2 receptor agonist 8 inhibits the migration of U87 .

HY-N8501

Emestrin	Bacterial	Infection
Emestrin is a mycotoxin originally isolated from E. striata that has antimicrobial, immunomodulatory, and cytotoxic activities. It is active against the fungi C. albicans and C. neoformans, as well as the bacteria E. coli, S. aureus, and methicillin-resistant S. aureus (MRSA; *IC₅₀*s=3.94, 0.6, 2.21, 4.55, and 2.21 μg/mL, respectively).2 Emestrin is a chemokine (C-C motif) receptor 2 (CCR2) antagonist (IC₅₀=5.4 μM in a radioligand binding assay using isolated human monocytes).3 Emestrin (0.1 μg/mL) induces apoptosis in HL-60 cells. It induces heart, thymus, and liver tissue necrosis in mice when administered at doses ranging from 18 to 30 mg/kg.

HY-W276819

PLK1-IN-9	Polo-like Kinase (PLK)	Cancer
PLK1-IN-9 (Compound M2) is an inhibitor for polo-like kinase 1 (PLK1), that inhibits PLK proteins modified with peptides 1010pT, cdc25c and PBIP, with *IC₅₀s of 1.6, 0.8 and 1.4 μM, respectively. PLK1-IN-9 inhibits proliferations of cancer cells HeLa, HL60, SNU387/499, HepG2, exhibits cytotoxicity and induces apoptosis*. PLK1-IN-9 inhibits tumor growth in HepG2 xenograft mouse model .

HY-149522

WK499	Bcl-2 Family Apoptosis	Cancer
BCL6-IN-10 (Compound WK499) is a BCL6 inhibitor. BCL6-IN-10 interrupts the binding of BCL6 to SMRT protein. BCL6-IN-10 induces cell apoptosis, cell cycle arrest and DNA damage. BCL6-IN-10 inhibits AML cell proliferation (IC₅₀s: 0.91, 1.63, 1.026, 7.42, 0.87, 0.85μM for OCl-AML3, THP1, MOLM13, HL60, KG1, NB4 cell respectively) .

HY-181023

PROTAC HDAC8 Degrader-3	PROTACs HDAC	Cancer
PROTAC HDAC8 Degrader-3 (Compound BP1) is an efficient and selective HDAC8 PROTAC degrader with a DC₅₀ of 20 nM. PROTAC HDAC8 Degrader-3 exhibits IC₅₀ for HDAC8 and CRBN of 0.46 and 7.5 μM, respectively. PROTAC HDAC8 Degrader-3 exhibits potent anti-proliferative activity against MM.1S and HL-60 cells. PROTAC HDAC8 Degrader-3 can be used for research on multiple myeloma and acute myeloid leukemia .

HY-103286R

PD176252 (Standard)	Reference Standards Bombesin Receptor	Cancer
PD176252 (Standard) is the analytical standard of PD176252 (HY-103286). This product is intended for research and analytical applications. PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC₅₀s of 0.31 and 0.66 μM in HL-60 cells.

Cat. No.	Nombre del producto	Category	Target	Chemical Structure